In vitro activity of OPT-80 against Clostridium difficile

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 6, 2004, Pages 2280-2282

  Ackermann, Grit ^a   Löffler, Birgit ^a   Adler, Daniela ^a   Rodloff, Arne C ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FUSIDIC ACID; LINEZOLID; MACROCYCLIC COMPOUND; METRONIDAZOLE; MOXIFLOXACIN; OPT 80; UNCLASSIFIED DRUG; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEROIDES FRAGILIS; CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG ACTIVITY; EUBACTERIUM; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; LACTOBACILLUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVOTELLA; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; RELAPSE; STRAIN DIFFERENCE; STRAIN IDENTIFICATION;

ANTI-INFECTIVE AGENTS; BACTERIA, ANAEROBIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CULTURE MEDIA; GLYCOSIDES; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 2542506441     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.6.2280-2282.2004     Document Type: Article

References (12)

1. Brazier, J. S., W. Fawley, J. Freeman, and M. H. Wilcox. 2001. Reduced susceptibility of Clostridium difficile to metronidazole. J. Antimicrob. Chemother. 48:741-742.
2. Deutsches Institut für Normung. 2000. Medizinische Mikrobiologie und Immunologie: Diagnostische Verfahren. Deutsches Institut für Normung, Berlin, Germany.
3. Fekety, R., L. V. McFarland, C. M. Surawicz, R. N. Greenberg, G. W. Elmer, and M. E. Mulligan. 1997. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin. Infect. Dis. 24:324-333.
4. Jang, S. S., L. M. Hansen, J. E. Breher, D. A. Riley, K. D. Madigan, Y. J. Tang, J. Silva, Jr., and D. C. Hirsh. 1997. Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant strains. Clin. Infect. Dis. 25:S266-S267.
5. Kyne, L., M. B. Hamel, R. Polavaram, and C. P. Kelly. 2002. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34:346-353.
6. McFarland, L. V., C. M. Surawicz, M. Rubin, R. Fekety, G. W. Elmer, and R. N. Greenberg. 1999. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect. Control Hosp. Epidemiol. 20:43-50.
7. National Committee for Clinical Laboratory Standards. 1997. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 4th ed. Approved standard M11-A4. National Committee for Clinical Laboratory Standards, Wayne, PA.
8. Peláez, T., L. Alcala, R. Alonso, M. Rodriguez-Creixems, J. M. Garcia-Lechuz, and E. Bouza. 2002. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob. Agents Chemother. 46:1647-1650.
9. Sergio, S., G. Pirall, R. White, and F. Parenti. 1975. Lipiarmycin, a new antibiotic from actinoplanes. III. Mechanism of action. J. Antibiot. 28:543-549.
10. Swanson, R. N., D. J. Hardy, N. L. Shipkowitz, C. W. Hanson, N. C. Ramer, P. B. Fernandes, and J. J. Clement. 1991. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob. Agents Chemother. 35:1108-1111.
11. Theriault, R. J., J. P. Karwowski, M. Jackson, R. L. Girolami, G. N. Sunga, C. M. Vojtko, and L. J. Coen. 1987. Tiacumicins, a novel complex of 18-membered macrolide antibiotics. J. Antibiot. 40:567-574.
12. Wong, S. S.-S., P. C.-Y. Woo, W. K. Luk, and K.-Y. Yuen. 1999. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn. Microbiol. Infect. Dis. 34:1-6.